Taysha Gene Therapies Inc (NASDAQ: TSHA) on Monday, soared 6.74% from the previous trading day, before settling in for the closing price of $5.49. Within the past 52 weeks, TSHA’s price has moved between $1.05 and $5.95.
During the last 5-year period, the sales drop of Healthcare Sector giant was -63.99%. The company achieved an average annual earnings per share of -0.86%. With a float of $223.27 million, this company’s outstanding shares have now reached $273.92 million.
Taysha Gene Therapies Inc (TSHA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Taysha Gene Therapies Inc is 18.49%, while institutional ownership is 89.59%. The most recent insider transaction that took place on Dec 01 ’25, was worth 1,172,812. In this transaction President and Head of R&D of this company sold 260,047 shares at a rate of $4.51, taking the stock ownership to the 1,006,439 shares. Before that another transaction happened on Nov 28 ’25, when Company’s President and Head of R&D sold 110,125 for $4.75, making the entire transaction worth $523,094. This insider now owns 1,006,439 shares in total.
Taysha Gene Therapies Inc (TSHA) Earnings and Forecasts
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.07 earnings per share (EPS) for the period topping the consensus outlook (set at -0.08) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.28% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Taysha Gene Therapies Inc (TSHA) is currently performing well based on its current performance indicators. A quick ratio of 10.47 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 254.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.45 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Looking closely at Taysha Gene Therapies Inc (NASDAQ: TSHA), its last 5-days average volume was 5.07 million, which is a jump from its year-to-date volume of 3.88 million. As of the previous 9 days, the stock’s Stochastic %D was 55.08%.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 97.22%, which indicates a significant increase from 94.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.34 in the past 14 days, which was higher than the 0.29 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.79, while its 200-day Moving Average is $3.10. However, in the short run, Taysha Gene Therapies Inc’s stock first resistance to watch stands at $6.04. Second resistance stands at $6.22. The third major resistance level sits at $6.48. If the price goes on to break the first support level at $5.60, it is likely to go to the next support level at $5.34. Should the price break the second support level, the third support level stands at $5.16.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
Market capitalization of the company is 1.61 billion based on 273,919K outstanding shares. Right now, sales total 8,330 K and income totals -89,300 K. The company made 1,990 K in profit during its latest quarter, and -26,880 K in sales during its previous quarter.
